REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
13/04/2026
Voltar para busca
Dado oficial do USPTO
XIROMED
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
XIROMED
ST13
US500000086949502Classe
5, 35, 39, 42
Pedido
86949502
Registro
6317944
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
14/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 35, 39, 42
Data de depósito
23/03/2016
Data de registro
13/04/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
13/04/2021
Última transação
14/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
21
Localização do titular
MADRID, ES
Examinador
HOWARD, PARKER WALDRIP
Unidade examinadora
M80
Localização atual
GENERIC WEB UPDATE
Titulares e representantes
Titulares
INSUD PHARMA, S.L.U.
CHEMO ESPAÑA, S.L.
Representantes
Arturo Perez-Guerrero MARCAS ESTADOS UNIDOS
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 39Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparation for use in treating digestive diseases and disordersgynecological diseases and disordershormonal diseases and disordersblood disorderscancercardiovascular diseasesvascular diseasesgastrointestinal diseasesgenitourinary diseasesimmunologic diseasesinfectious diseasesinflammatory diseasesmetabolic diseases and disorderspsychiatric diseasesmusculoskeletal systemrespiratory systemcirculatory systemviral diseasesglaucomadental and oral diseasesheadachesmigraineobesityhepatic treatmentscholesterolblood pressure and rheumatic treatments; all of the foregoing excluding pharmaceutical preparations for the treatment and/or management of sleep disordersnarcolepsycataplexyand/or excessive daytime sleepiness (EDS); veterinary preparation for treating digestive diseases and disordersgynecological diseases and disordersblood disorderscancercardiovascular diseasesvascular diseasesgastrointestinal diseasesgenitourinary diseasesimmunologic diseasesinfectious diseasesinflammatory diseasesmetabolic diseases and disordersmusculoskeletal systemrespiratory systemcirculatory systemviral diseasesglaucomadental and oral diseasesheadachesmigraineobesityhepatic treatmentscholesterolblood pressure and rheumatic treatments; all of the foregoing excluding pharmaceutical preparations for the treatment and/or management of sleep disordersnarcolepsycataplexyand/or excessive daytime sleepiness (EDS)
Classe 35
Sales promotion for othersbusiness management assistancebusiness management consultancy and market research; presentation of goods by any means of communications for retailing purposes; commercial administration of the licensing of the goods and services of others; organisation of exhibitionstrade fairs or congresses for commercial or advertising purposes; all the aforesaid in this class relating to pharmaceutical businesses and for pharmaceutical preparations
Classe 39
Distributiondelivery of pharmaceutical preparations; Transportpackaging and storage services for pharmaceutical preparations
Classe 42
ChemicalBiological and Pharmaceutical research services; development of pharmaceutical preparations; clinical trial studies of pharmaceutical preparations for others; evaluation and inspection of pharmaceutical preparations
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/01/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/01/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/01/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
14/09/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
14/09/2021
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
14/09/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
14/09/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
14/09/2021
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
14/09/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
13/04/2021
AOUM
ASSIGNMENT OF OWNERSHIP UPDATED MANUALLY
22/03/2021
TMBN
TTAB RELEASE CASE TO TRADEMARKS
05/03/2021
OP.T
OPPOSITION TERMINATED NO. 999999
05/03/2021
OP.D
OPPOSITION DISMISSED NO. 999999
05/03/2021
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
16/01/2019
OP.I
OPPOSITION INSTITUTED NO. 999999
09/10/2017
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
11/05/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/04/2017
PUBO
PUBLISHED FOR OPPOSITION
11/04/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/03/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
06/03/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/03/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/02/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/02/2017
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
13/02/2017
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
03/02/2017
GNSI
INQUIRY TO SUSPENSION E-MAILED
03/02/2017
CNSI
SUSPENSION INQUIRY WRITTEN
03/02/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
27/01/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
27/01/2017
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
24/01/2017
ALIE
ASSIGNED TO LIE
23/01/2017
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
11/07/2016
GNSL
LETTER OF SUSPENSION E-MAILED
11/07/2016
CNSL
SUSPENSION LETTER WRITTEN
11/07/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
11/07/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/07/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
11/07/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/07/2016
DOCK
ASSIGNED TO EXAMINER
06/07/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/03/2016
NWAP
NEW APPLICATION ENTERED
26/03/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace XIROMED ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.